Editorial comment on: Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats.
Antonella
A
Giannantoni
D000283:Administration, Intravesical; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage*; D003520:Cyclophosphamide; D003556:Cystitis / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D051381:Rats; D018078:Receptors, Prostaglandin E / Q000037:antagonists & inhibitors*; D058309:Receptors, Prostaglandin E, EP4 Subtype; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology
D052246:Cyclooxygenase 2 Inhibitors; D018078:Receptors, Prostaglandin E; D058309:Receptors, Prostaglandin E, EP4 Subtype; D003520:Cyclophosphamide; D019274:Botulinum Toxins, Type A